Prometheus Biosciences

63 articles about Prometheus Biosciences

• 

  Merck Leans into Immunology with $10.8B Prometheus Buy

  4/17/2023

  Merck will acquire immune-focused Prometheus Biosciences for approximately $10.8 billion, picking up a mid-stage ulcerative colitis and Crohn's asset.

• Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.

  4/16/2023

  Merck, known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.

• Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

  3/9/2023

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today announced that management will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 10:40 AM ET.

• Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress

  2/28/2023

  Prometheus Biosciences, Inc. (Nasdaq: RXDX) today reported financial results for the quarter and full-year ended December 31, 2022 and highlighted recent corporate progress.

• Prometheus Biosciences Announces Two Oral Presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

  2/22/2023

  Prometheus Biosciences, Inc. (Nasdaq: RXDX) today announced two oral presentations on PRA023 at the 18th Congress of European Crohn’s and Colitis Organisation (ECCO), taking place in Copenhagen, Denmark, March 1- 4, 2023.

• Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference

  2/9/2023

  Prometheus Biosciences, Inc. (Nasdaq: RXDX) today announced that management will conduct a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023 at 12:00 PM ET.

• Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Prometheus Biosciences, Inc. today announced that Mark McKenna, Chairman and Chief Executive Officer and Allison Luo, MD, Chief Medical Officer, will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 3:45 p.m. PST.

• Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock

  12/9/2022

  Prometheus Biosciences, Inc. announced the pricing of an underwritten offering of 4,545,455 shares of its common stock at a price to the public of $110 per share.

• 

  Prometheus’ Anti-TL1A Monoclonal Antibody Notches Wins in Colitis, Crohn's 

  12/7/2022

  ​​​​​​​Findings from the Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that Prometheus’ PRA023 is potentially safe and effective for treating ulcerative colitis and Crohn’s disease.

• Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock

  12/7/2022

  Prometheus Biosciences, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250 million of shares of its common stock in an underwritten public offering.

• Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

  12/7/2022

  Prometheus Biosciences, Inc. today reported results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023 demonstrating strong efficacy and favorable safety results in both studies.

• Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

  11/9/2022

  Prometheus Biosciences, Inc. (Nasdaq: RXDX) today reported financial results for the quarter ended September 30, 2022 and highlighted recent corporate progress.

• Prometheus Biosciences to Participate at November 2022 Healthcare Conferences

  11/1/2022

  Prometheus Biosciences, Inc. announced that management will conduct fireside chats at the following healthcare conferences.

• 

  FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

  10/7/2022

  The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.

• Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052

  10/3/2022

  Prometheus Biosciences, Inc. today announced the U.S. Food and Drug Administration (FDA) cleared the company to proceed with a clinical trial under its Investigational New Drug Application (IND) for PRA052 in ulcerative colitis.

• Prometheus Biosciences to Participate at September Healthcare Conferences

  8/31/2022

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences.

• Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

  8/11/2022

  Prometheus Biosciences, Inc. reported financial results for the quarter ended June 30, 2022 and highlighted recent corporate progress.

• 

  Clinical Catch-Up: Prometheus, Algernon, Seelos, Inozyme and Takeda

  7/25/2022

  Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.

• Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022

  7/18/2022

  Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced it will host a virtual R&D Day for analysts and investors at 9:00 am ET on Tuesday, July 26, 2022.

• Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis

  7/18/2022

  Prometheus Biosciences, Inc. today announced the completion of enrollment for Cohort 1 of the ARTEMIS-UC global Phase 2 study of PRA023 in ulcerative colitis (UC).